Abstract:The amyloid β peptide (Aβ) starting with pyroglutamate (pE) at position 3 and ending at position 42 (Aβ3pE-42) is a dominant species that accumulates in the Alzheimer’s disease (AD) brain. Consistently, a therapeutic antibody raised against this species, donanemab, has been shown to be effective in recent clinical trials. While the primary Aβ species produced physiologically is Aβ1-40/42, an explanation for how and why this physiological Aβ is converted to the pathological form has remained elusive. The conversion of Aβ1-42 to Aβ3pE-42 is likely to take place after deposition of Aβ1-42 given that Aβ3pE-42 plaques arise significantly later than Aβ1-42 deposition in the brains of single knock-in and APP-transgenic mice. Here, we present experimental evidence that accounts for the aging-associated Aβ3pE-42 deposition: [1] Aβ3pE-42 is metabolically more stable than other AβX-42 species; [2] Deficiency of neprilysin (NEP), the major Aβ-degrading enzyme, induces a relatively selective deposition of Aβ3pE-42 in APP-Tg mice. [3] Aβ3pE-42 deposition always colocalizes with cored plaques in both APP-Tg and App knock-in mouse brains; [4] Aβ3E-42, an immediate precursor of Aβ3pE-42, as well as Aβ2A-42 and Aβ4F-42 are more short-lived than Aβ1-42 , indicating that simple N-terminal truncation that can arise enzymatically or spontaneously makes AβX-42 easier to catabolize. Consistently, newly generated knock-in mice, and , showed no detectable Aβ pathology even after aging, indicating that the Aβ3E-42 and Aβ3Q-42 species are extremely labile to the catabolic system and that the E/Q cyclase activity present in mouse brain is insufficient for Aβ3pE-42 generation. In addition, a deficiency of NEP facilitated Aβ3pE-42 deposition. Of note, we identified a trace amount of Aβ3pE-42 and its immediate precursor, Aβ3E-42, in the insoluble fraction of NEP-deficient APP-Tg mouse brains. Aβ3pE-42 is thus likely to be a probabilistic by-product of Aβ1-42 metabolism that selectively accumulates over a long-time range of brain aging. It is likely produced in the solid state or at the solid-liquid interface. Our findings suggest that anti-Aβ therapies will probably be most effective if given before Aβ3pE-42 deposition takes place.

Aβ43 aggregates exhibit enhanced prion-like seeding activity in mice

Potent amyloidogenicity and pathogenicity of Aβ43

Seeding and Cross-Seeding Aggregations of Aβ40 and Its N-Terminal-Truncated Peptide Aβ11-40.

Synthetic Aβ Peptides Acquire Prion-Like Properties in the Brain.

Comparison of neurotoxicity of different aggregated forms of A<i>β</i>40, A<i>β</i>42 and A<i>β</i>43 in cell cultures

Modulation of Aggregation and Structural Polymorphisms of Β-Amyloid Fibrils in Cellular Environments by Pyroglutamate-3 Variant Cross-Seeding.

Abeta42 is essential for parenchymal and vascular amyloid deposition in mice.

Heterotypic Seeding Generates Mixed Amyloid Polymorphs

Comparison Of Neurotoxicity Of Different Aggregated Forms Of A Beta 40, A Beta 42 And A Beta 43 In Cell Cultures

A Beta 42 Mutants with Different Aggregation Profiles Induce Distinct Pathologies in Drosophila

Unique seeding profiles and prion-like propagation of synucleinopathies are highly dependent on the host in human α-synuclein transgenic mice

Induction and characterisation of Abeta and tau pathology in AppNL-F/NL-F mice following inoculation with Alzheimer's disease brain homogenate

Cross-Seeded Fibrillation Induced by Pyroglutamate-3 and Truncated Aβ40 Variants Leads to Aβ40 Structural Polymorphism Modulation and Elevated Toxicity.

Injected Amyloid Beta in the Olfactory Bulb Transfers to Other Brain Regions via Neural Connections in Mice

Intraneuronal Abeta42 accumulation in human brain.

Intraneuronal Alzheimer A Beta 42 Accumulates in Multivesicular Bodies and is Associated with Synaptic Pathology

Intracisternal Injection of Beta-Amyloid Seeds Promotes Cerebral Amyloid Angiopathy

Metabolic resistance of Aβ3pE-42, target epitope of the anti-Alzheimer therapeutic antibody, donanemab

Aβ1-16 Can Aggregate and Induce the Production of Reactive Oxygen Species, Nitric Oxide, and Inflammatory Cytokines.

Amyloid-β Activates Microglia and Regulates Protein Expression in a Manner Similar to Prions.

Trans‐seeding of Alzheimer‐related tau protein by a yeast prion